InnoCare Pharma Statistics

Total Valuation

InnoCare Pharma has a market cap or net worth of HKD 26.90 billion. The enterprise value is 21.06 billion.

Market Cap	26.90B
Enterprise Value	21.06B

Important Dates

The next estimated earnings date is Tuesday, August 19, 2025.

Earnings Date	Aug 19, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has decreased by -7.72% in one year.

Current Share Class	1.49B
Shares Outstanding	1.76B
Shares Change (YoY)	-7.72%
Shares Change (QoQ)	+11.25%
Owned by Insiders (%)	21.56%
Owned by Institutions (%)	35.52%
Float	1.37B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	20.48
PB Ratio	3.71
P/TBV Ratio	3.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-70.09
EV / Sales	16.04
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-67.21

Financial Position

The company has a current ratio of 7.84, with a Debt / Equity ratio of 0.23.

Current Ratio	7.84
Quick Ratio	7.32
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	-5.29
Interest Coverage	-9.56

Financial Efficiency

Return on equity (ROE) is -4.24% and return on invested capital (ROIC) is -3.19%.

Return on Equity (ROE)	-4.24%
Return on Assets (ROA)	-2.63%
Return on Invested Capital (ROIC)	-3.19%
Return on Capital Employed (ROCE)	-4.79%
Revenue Per Employee	1.21M
Profits Per Employee	-275,930
Employee Count	1,089
Asset Turnover	0.13
Inventory Turnover	1.40

Taxes

In the past 12 months, InnoCare Pharma has paid 2.34 million in taxes.

Income Tax	2.34M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +182.98% in the last 52 weeks. The beta is 0.99, so InnoCare Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.99
52-Week Price Change	+182.98%
50-Day Moving Average	11.19
200-Day Moving Average	7.93
Relative Strength Index (RSI)	59.57
Average Volume (20 Days)	22,427,423

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCare Pharma had revenue of HKD 1.31 billion and -300.49 million in losses. Loss per share was -0.18.

Revenue	1.31B
Gross Profit	1.15B
Operating Income	-431.94M
Pretax Income	-311.51M
Net Income	-300.49M
EBITDA	-358.17M
EBIT	-431.94M
Loss Per Share	-0.18

Full Income Statement

Balance Sheet

The company has 7.51 billion in cash and 1.66 billion in debt, giving a net cash position of 5.86 billion or 3.33 per share.

Cash & Cash Equivalents	7.51B
Total Debt	1.66B
Net Cash	5.86B
Net Cash Per Share	3.33
Equity (Book Value)	7.25B
Book Value Per Share	4.03
Working Capital	7.39B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -241.22 million and capital expenditures -72.13 million, giving a free cash flow of -313.35 million.

Operating Cash Flow	-241.22M
Capital Expenditures	-72.13M
Free Cash Flow	-313.35M
FCF Per Share	-0.18

Full Cash Flow Statement

Margins

Gross margin is 87.74%, with operating and profit margins of -32.89% and -22.88%.

Gross Margin	87.74%
Operating Margin	-32.89%
Pretax Margin	-23.72%
Profit Margin	-22.88%
EBITDA Margin	-27.27%
EBIT Margin	-32.89%
FCF Margin	n/a

Dividends & Yields

InnoCare Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	7.72%
Shareholder Yield	n/a
Earnings Yield	-1.12%
FCF Yield	-1.16%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoCare Pharma has an Altman Z-Score of 2.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.58
Piotroski F-Score	4